CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · IEX Real-Time Price · USD
1.66
+0.01 (0.61%)
At close: Aug 19, 2022 4:00 PM
1.64
-0.02 (-1.20%)
After-hours:
Aug 19, 2022 4:06 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
|
69.57 | 100.36 | 57.49 | 59.5 | 71.62 | 15.04 | 7.71 | 5.08 | 0.89 |
| Revenue Growth (YoY)
|
-30.68% | 74.58% | -3.38% | -16.92% | 376.12% | 95.06% | 51.90% | 471.73% | - |
| Gross Profit
|
69.57 | 100.36 | 57.49 | 59.5 | 71.62 | 15.04 | 7.71 | 5.08 | 0.89 |
| Selling, General & Admin
|
39.16 | 36.03 | 36.77 | 33.51 | 25.61 | 19.87 | 12.56 | 6.54 | 4.95 |
| Research & Development
|
114.19 | 112.94 | 131.62 | 103.87 | 92.28 | 54.76 | 28.36 | 28.3 | 10.89 |
| Operating Expenses
|
153.35 | 148.97 | 168.38 | 137.38 | 117.88 | 74.63 | 40.92 | 34.84 | 15.84 |
| Operating Income
|
-83.78 | -48.61 | -110.9 | -77.87 | -46.26 | -59.59 | -33.2 | -29.77 | -14.96 |
| Interest Expense / Income
|
0 | 0 | 0 | 0 | 0 | 0 | 1.73 | 0.49 | 0.25 |
| Other Expense / Income
|
-0.17 | -1.81 | -8.23 | -7.57 | -2.65 | -0.67 | 0.43 | 0.05 | -0.08 |
| Pretax Income
|
-83.61 | -46.8 | -102.67 | -70.3 | -43.61 | -58.92 | -35.36 | -30.3 | -15.13 |
| Income Tax
|
0 | -13.91 | -0.43 | 14.3 | -0.51 | -0.02 | 0.01 | 0.01 | 0.01 |
| Net Income
|
-83.61 | -32.89 | -102.24 | -84.6 | -43.1 | -58.9 | -35.37 | -30.31 | -15.14 |
| Preferred Dividends
|
0 | 0 | 0 | 0 | 0 | 0 | 6.71 | 4.57 | 3.75 |
| Net Income Common
|
-83.61 | -32.89 | -102.24 | -84.6 | -43.1 | -58.9 | -42.08 | -34.88 | -18.89 |
| Shares Outstanding (Basic)
|
64 | 46 | 45 | 42 | 37 | 36 | 9 | 1 | 1 |
| Shares Outstanding (Diluted)
|
64 | 46 | 45 | 42 | 37 | 36 | 9 | 1 | 1 |
| Shares Change
|
39.01% | 1.79% | 8.81% | 12.10% | 2.57% | 321.57% | 768.69% | 28.11% | - |
| EPS (Basic)
|
-1.30 | -0.71 | -2.26 | -2.03 | -1.16 | -1.63 | -4.90 | -35.25 | -24.46 |
| EPS (Diluted)
|
-1.30 | -0.71 | -2.26 | -2.03 | -1.16 | -1.63 | -4.90 | -35.25 | -24.46 |
| Free Cash Flow Per Share
|
-1.88 | 0.06 | -3.18 | -1.90 | 4.54 | -0.12 | -3.38 | 30.46 | -11.32 |
| Gross Margin
|
100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin
|
-120.40% | -48.40% | -192.90% | -130.90% | -64.60% | -396.10% | -430.50% | -586.30% | -1684.20% |
| Profit Margin
|
-120.20% | -32.80% | -177.80% | -142.20% | -60.20% | -391.50% | -545.60% | -686.90% | -2127.70% |
| Free Cash Flow Margin
|
-173.40% | 2.90% | -250.40% | -133.30% | 235.70% | -27.60% | -376.20% | 593.60% | -984.20% |
| Effective Tax Rate
|
0.00% | 29.73% | 0.42% | -20.35% | 1.18% | 0.03% | -0.03% | -0.03% | -0.07% |
| EBITDA
|
-77.77 | -41.34 | -97.39 | -68.42 | -41.95 | -57.19 | -32.43 | -29.03 | -14.22 |
| EBITDA Margin
|
-111.80% | -41.20% | -169.40% | -115.00% | -58.60% | -380.20% | -420.50% | -571.80% | -1601.80% |
| Depreciation & Amortization
|
5.84 | 5.46 | 5.28 | 1.88 | 1.66 | 1.73 | 1.21 | 0.78 | 0.66 |
| EBIT
|
-83.61 | -46.8 | -102.67 | -70.3 | -43.61 | -58.92 | -33.63 | -29.81 | -14.88 |
| EBIT Margin
|
-120.20% | -46.60% | -178.60% | -118.10% | -60.90% | -391.70% | -436.10% | -587.20% | -1675.60% |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).